SIBO

IBS vs SIBO: How to Tell the Difference

April 25, 202610 min readBy GLP1Gut Team
IBSSIBOIBS vs SIBOmisdiagnosisbreath test

📋TL;DR: IBS is a symptom-based diagnosis of exclusion defined by Rome IV criteria. SIBO is a measurable bacterial overgrowth in the small intestine. Studies show 60-78% of IBS patients test positive for SIBO on breath testing. Key SIBO differentiators include symptoms within 90 minutes of eating, improvement with fasting, post-food-poisoning onset, and response to rifaximin.

What We Know

  • 60-78% of patients meeting IBS criteria test positive for SIBO on lactulose breath testing (Pimentel et al. 2000, Lin 2004).
  • IBS is diagnosed using Rome IV symptom criteria without any required testing for bacterial overgrowth.
  • SIBO can be identified through validated breath tests measuring hydrogen, methane, and hydrogen sulfide gases.
  • Rifaximin (550 mg three times daily for 14 days) is FDA-approved for IBS-D and has documented efficacy in SIBO (Pimentel et al. 2011).
  • Anti-vinculin and anti-CdtB antibody testing (ibs-smart) can identify post-infectious mechanisms linking food poisoning to IBS/SIBO (Pimentel et al. 2015).

What We Don't Know

  • Whether all IBS patients should be routinely screened for SIBO remains debated among gastroenterologists.
  • The exact prevalence of SIBO in IBS varies widely (4-78%) depending on the diagnostic method and study population.
  • Whether treating SIBO in IBS patients produces lasting symptom improvement or only temporary relief is still under investigation.
  • How much of IBS symptom burden is directly caused by bacterial overgrowth versus other mechanisms like visceral hypersensitivity.
  • Optimal breath test thresholds and protocols for detecting SIBO in IBS populations are not fully standardized.

Between 60% and 78% of people diagnosed with irritable bowel syndrome test positive for small intestinal bacterial overgrowth. That single statistic explains why so many IBS patients cycle through dietary changes, fiber supplements, and antispasmodics without lasting relief. IBS and SIBO share the same headline symptoms, bloating, abdominal pain, diarrhea, and constipation, but they are fundamentally different conditions. IBS is a label applied when symptoms match a checklist and nothing else is found. SIBO is a specific, testable imbalance with identifiable causes and targeted treatments. Understanding where these two conditions overlap and where they diverge is the first step toward getting the right diagnosis.

What is IBS?

Irritable bowel syndrome is a functional gastrointestinal disorder defined by the Rome IV criteria. To receive an IBS diagnosis, a patient must have recurrent abdominal pain at least one day per week for the past three months, associated with two or more of the following: pain related to defecation, a change in stool frequency, or a change in stool form. Symptoms must have started at least six months before diagnosis. IBS is classified into subtypes: IBS-D (diarrhea-predominant), IBS-C (constipation-predominant), IBS-M (mixed), and IBS-U (unsubtyped).

The critical point is that IBS is a diagnosis of exclusion. There is no blood test, imaging study, or biomarker that confirms IBS. The Rome IV criteria are symptom-based, and the diagnosis is made after ruling out other conditions like celiac disease, inflammatory bowel disease, and colorectal cancer. Notably, SIBO testing is not part of the standard IBS diagnostic workup in most clinical settings.

What is SIBO?

Small intestinal bacterial overgrowth is defined as an excessive number of bacteria in the small intestine, where the bacterial population is normally kept low by gastric acid, bile, the migrating motor complex (MMC), and the ileocecal valve. When these defenses fail, bacteria from the colon migrate upward or resident small intestinal bacteria multiply unchecked. These bacteria ferment carbohydrates that should be absorbed in the small intestine, producing hydrogen, methane, or hydrogen sulfide gas. The result is bloating, distension, pain, and altered bowel habits.

Unlike IBS, SIBO has a testable mechanism. Breath testing can detect the gases produced by overgrown bacteria. Jejunal aspirate culture can measure bacterial counts directly (though this is rarely done outside research). The 2017 North American Consensus defines positive SIBO as a hydrogen rise of 20 ppm or more above baseline within 90 minutes on a breath test, methane at 10 ppm or more at any point, or hydrogen sulfide at 3 ppm or more on a trio-smart test.

How do IBS and SIBO symptoms overlap?

The symptom overlap between IBS and SIBO is extensive, which is precisely why misdiagnosis is so common. Both conditions produce bloating (the most frequently reported symptom in both), abdominal pain or cramping, diarrhea, constipation, and excessive gas. Both can cause fatigue, brain fog, and food intolerances. A clinician looking only at a symptom list cannot distinguish one from the other.

SymptomIBSSIBO
BloatingVery commonVery common
Abdominal painDefining feature (Rome IV)Common, often post-meal
DiarrheaIBS-D subtypeHydrogen-dominant SIBO
ConstipationIBS-C subtypeMethane/IMO-dominant SIBO
Excessive gasCommonCommon, often within 90 min of eating
Food intolerancesCommon, variable triggersCommon, especially high-FODMAP foods
NauseaOccasionalCommon, especially post-meal
Fatigue/brain fogReported frequentlyReported frequently

What are the key differentiators between IBS and SIBO?

Despite the symptom overlap, several clinical features point more strongly toward SIBO than uncomplicated IBS. None of these are definitive on their own, but when multiple indicators are present, SIBO testing becomes a high-value next step.

  • Symptoms within 90 minutes of eating. In SIBO, bacteria begin fermenting food shortly after it reaches the small intestine, producing gas and bloating quickly. In IBS without SIBO, bloating may be more diffuse and less consistently tied to meals.
  • Improvement with fasting. Because SIBO symptoms are driven by bacterial fermentation of food, many SIBO patients notice that symptoms decrease significantly during prolonged fasting (12+ hours). This pattern is less consistent in IBS driven by visceral hypersensitivity or motility issues alone.
  • Post-food-poisoning onset. A clear history of gastroenteritis followed by the gradual development of IBS symptoms strongly suggests post-infectious SIBO. The Pimentel group has shown that food poisoning can trigger autoimmune damage to the interstitial cells of Cajal via anti-vinculin antibodies, impairing the MMC and allowing bacterial overgrowth.
  • Response to rifaximin. Rifaximin (Xifaxan) is FDA-approved for IBS-D but works specifically by reducing bacterial load in the small intestine. If a patient improves on rifaximin but relapses after the course ends, that pattern strongly suggests underlying SIBO rather than IBS alone.
  • Elevated breath test gases. A positive lactulose or glucose breath test provides objective evidence of bacterial overgrowth that symptom-based IBS criteria cannot capture.

â„šī¸A post-food-poisoning onset is one of the strongest clinical predictors of SIBO. The ibs-smart blood test measures anti-vinculin and anti-CdtB antibodies to confirm the post-infectious mechanism. A positive result does not diagnose active SIBO directly but identifies the autoimmune motility damage that causes it.

How are IBS and SIBO diagnosed differently?

IBS is diagnosed clinically using the Rome IV criteria. The physician confirms that symptoms meet the frequency and duration thresholds, rules out red-flag conditions (celiac, IBD, colorectal cancer) with basic bloodwork and possibly a colonoscopy, and applies the IBS label. No test confirms IBS. It is what remains after other diagnoses have been excluded.

SIBO diagnosis requires a specific test. The lactulose breath test is the most commonly used option in clinical practice. The glucose breath test is an alternative with higher specificity but lower sensitivity. The trio-smart test adds hydrogen sulfide measurement. The ibs-smart blood test identifies the post-infectious autoimmune mechanism. In research settings, jejunal aspirate culture (positive at greater than 10^3 CFU/mL) serves as the reference standard but is rarely used clinically due to its invasive nature and contamination risk.

Diagnostic FeatureIBSSIBO
Diagnostic methodSymptom criteria (Rome IV)Breath test, aspirate culture
Confirmatory test exists?NoYes
Requires ruling out other conditions?Yes (diagnosis of exclusion)No (positive test confirms)
Standard workup includes SIBO testing?Usually noN/A
Antibody testing available?NoYes (ibs-smart for post-infectious)

How do treatment approaches differ?

IBS treatment is primarily symptom management. Standard recommendations include dietary modification (often a low-FODMAP diet), fiber supplementation, antispasmodics like hyoscyamine or dicyclomine, loperamide for diarrhea, and occasionally low-dose tricyclic antidepressants or SSRIs for pain modulation. These approaches aim to reduce symptoms without addressing a specific underlying cause.

SIBO treatment targets the bacterial overgrowth directly. The first-line pharmaceutical approach is rifaximin, 550 mg three times daily for 14 days, which has a roughly 44% response rate in clinical trials (Pimentel et al. 2011, TARGET 3 trial). For methane-dominant SIBO (IMO), rifaximin is combined with neomycin (500 mg twice daily) or metronidazole. Herbal antimicrobial protocols using combinations of berberine, oregano oil, neem, and allicin have shown comparable efficacy to rifaximin in at least one study (Chedid et al. 2014). After eradication, prokinetic therapy (low-dose erythromycin, prucalopride, or low-dose naltrexone) is often used to restore MMC function and prevent relapse.

âš ī¸Do not self-treat with antibiotics or herbal antimicrobials based on symptom suspicion alone. Get tested first. Treatment without diagnosis can mask other conditions, create antibiotic resistance, and disrupt your large intestinal microbiome unnecessarily.

Can you have both IBS and SIBO at the same time?

Yes, and this is common. SIBO can be the underlying cause of IBS symptoms, or it can coexist with IBS that has additional contributing factors like visceral hypersensitivity, altered gut-brain signaling, or psychological stress. Treating the SIBO component may resolve symptoms entirely in some patients or significantly reduce symptom burden while leaving a residual IBS component that requires separate management. The Pimentel group's research suggests that in many cases, what is diagnosed as IBS is actually SIBO that has never been tested for. The 60-78% overlap figure from the Pimentel 2000 and Lin 2004 studies supports this interpretation, though the exact proportion varies by study and diagnostic method used.

Frequently Asked Questions

Can IBS turn into SIBO?

IBS itself does not transform into SIBO. However, the motility problems that contribute to IBS, particularly a dysfunctional migrating motor complex, create conditions that allow SIBO to develop. Medications used for IBS (like opioids for pain or anticholinergics) can also slow motility enough to promote bacterial overgrowth. Many patients diagnosed with IBS likely had undetected SIBO from the start.

Should every IBS patient be tested for SIBO?

This remains debated. Current ACG guidelines do not recommend routine SIBO testing for all IBS patients. However, many SIBO specialists argue that testing is warranted given the high overlap. At minimum, patients with IBS who are not responding to standard treatments, who have a post-food-poisoning onset, or who report symptoms strongly tied to meals should be tested.

If I test positive for SIBO, does that mean I do not have IBS?

Not necessarily. A positive SIBO test means you have bacterial overgrowth that may be causing or contributing to your symptoms. Some patients find that treating SIBO resolves their IBS symptoms completely. Others still meet IBS criteria after SIBO treatment, suggesting both conditions are present. SIBO treatment is still worthwhile because it addresses a treatable component of your symptoms.

How long does it take to get a SIBO breath test?

The test itself takes 2-3 hours (depending on whether glucose or lactulose substrate is used). You need 24 hours of dietary preparation beforehand and a 12-hour fast. At-home kits like trio-smart can be ordered by your physician and completed at home, with results typically returned within 5-7 business days. In-office testing provides same-day results at some clinics.

Is SIBO curable while IBS is not?

SIBO can be eradicated with antibiotics or herbal antimicrobials, but it recurs in roughly 44% of patients within 9 months if the underlying cause (impaired motility, structural issues, or medication effects) is not addressed. IBS is considered a chronic condition managed rather than cured. When SIBO is the primary driver of IBS symptoms, treating the SIBO and maintaining motility with prokinetics can produce lasting remission.

âš ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.

Key Takeaways

  1. 1IBS is diagnosed by symptoms alone. SIBO is diagnosed by measurable bacterial overgrowth. They can coexist.
  2. 2If your symptoms started after food poisoning, worsen within 90 minutes of eating, or improve when you fast, SIBO testing is worth pursuing.
  3. 3A lactulose or glucose breath test is the standard first step for distinguishing SIBO from uncomplicated IBS.
  4. 4Rifaximin works for both IBS-D and SIBO, which itself suggests significant overlap between the two conditions.
  5. 5Ask your gastroenterologist specifically about breath testing if you have been diagnosed with IBS but are not improving with standard treatments.

Sources & References

  1. 1.Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome - Pimentel et al., American Journal of Gastroenterology (2000)
  2. 2.Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis - Lin HC, Clinical Gastroenterology and Hepatology (2004)
  3. 3.Rifaximin therapy for patients with irritable bowel syndrome without constipation (TARGET 3) - Pimentel et al., New England Journal of Medicine (2011)
  4. 4.Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus - Rezaie et al., American Journal of Gastroenterology (2017)
  5. 5.Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects - Pimentel et al., PLOS ONE (2015)
  6. 6.Herbal therapies are equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth - Chedid et al., Global Advances in Health and Medicine (2014)
  7. 7.ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth - Pimentel et al., American Journal of Gastroenterology (2020)
  8. 8.Irritable Bowel Syndrome - Mayo Clinic Staff, Mayo Clinic (2023)

Medical Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult with a qualified healthcare professional before making changes to your diet, medications, or health regimen. GLP1Gut is a tracking tool, not a medical device.

Figure Out What's Actually Triggering You

An AI-powered meal and symptom tracker that connects what you eat to how you feel, built specifically for people on GLP-1 medications experiencing digestive side effects.